PURPOSE: We report the clinical efficacy of amniotic membrane transplantation which dyed by Chinese-ink and Davidson marking dye in patients of bullous keratopathy. METHODS: We performed permanent amniotic membrane transplantation in 23 eyes with bullous keratopathy during the period of October 1998 to May 2002. Simple amniotic membranes were transplanted in 9 eyes, Chinese-ink dyed amniotic membranes in 10 eyes, and Davidson marking dyed amniotic membranes in 4 eyes. RESULTS: 23 eyes were successfully transplanted by amniotic membrane. Most of patients with photophobia, pain, cosmetic problem had been satisfactory effects in Chinese-ink and Davidson marking dye groups and Davidson marking dye groups noted longer staining than Chinese-ink group. CONCLUSIONS: We suggest that dyed amniotic membrane transplantation may be effective method to release pain, photophobia, and cosmetic problem by stabilization of corneal surface than previous simple amniotic membrane transplantation in bullous keratopathy.
Amnion ; Humans ; Membranes* ; Photophobia

PURPOSE: This study was conducted to determine long-term results of Hydroxyapatite and Medpor(R) ocular implants. METHODS: This study was done on 108 eyes inserted with hydroxyapatite ocular implant and 82 eyes inserted with Medpor(R) ocular implant that were treated at the present hospital from January 1992 to December 2002. We compared the types, frequencies, and onset and treatment of complications according to the types of surgery. RESULTS: The clinical outcome for 14 months to 10 years (average: 57.6 months) was examined in the hydroxyapatite implantation group. The complications were implant exposure in 14 eyes (13%), soft tissue complication in 27 (25%), eyelid complication in 30 (27.8%), and complication due to Peg insertion in 21 (27.3%). The clinical outcome for 5 months to 4 years (average: 18.6 months) was examined in the Medpor(R) implant group. The complications involved were implant exposure in 5 eyes (6.1%), soft tissue complication in 14 (17.1%), eyelid complication in 25 (30.5%), and complication due to MCP insertion in 3 (16.7%). CONCLUSIONS: Active treatment for early complications and long-term follow-up for late complications are needed with hydroxyapatite and Medpor(R) implantations.
Durapatite* ; Eyelids ; Follow-Up Studies ; Orbit* ; Orbital Implants*

Objective: Moderate and severe behavioral and psychological symptoms of dementia (BPSD) often need medical treatment to improve symptoms. Agomelatine is a selective melatonergic (MT1/MT2) agonist that has normalizing effects on disturbed circadian rhythms and disrupted sleep−wake cycles. Its activity of 5HT-2C receptor antagonism is associated with lessening depression and anxiety and increasing slow-wave sleep. Based on past clinical records and current findings it suggests that agomelatine can improve BPSD for patients. This retrospective cohort study was designed to compare the BPSD before and after using agomelatine. Methods: Records of dementia cases who had ever received agomelatine treatment for BPSD in a general hospital setting during the past 2.5 years were identified and reviewed. Scores from before and after 3 months of treatment with agomelatine were collected for Neuropsychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI) to compare and analyze the difference of psychological and behavioral symptoms pre- and post-agomelatine used. Results: Records of 144 cases of dementia with BPSD who had ever used agomelatine from January 2015 to June 2017 were collected. All of the 112 cases had BPRS and CGI scores, of which 75 cases had additional NPI scores. Among these 112 cases, the BPRS and CGI scores were significantly improved in all types of dementia. NPI scores indicated that the use of agomelatine alleviated obvious symptoms and decreased overall distress, especially in the depression/poor mood, anxiety, and sleepight behavior. Conclusion It is consistent with an effective result of agomelatine in improving BPSD.